Smith & Nephew to host Capital Markets Days in London and New York

Smith & Nephew plc

Smith & Nephew Plc (LON:SN, NYSE: SNN), the global medical technology company, has announced that it will host Capital Markets Days for institutional investors and financial analysts in London and New York on Monday 8 and Thursday 11 December 2025 respectively.

​The London event will introduce Smith+Nephew’s new strategy following the conclusion of the 12-Point Plan, including mid-term priorities and financial goals. This will be held at The Royal College of Surgeons from 1pm to 5pm GMT / 8am to 12pm EST on 8 December.

​The New York event will provide greater detail on Smith & Nephew’s innovative portfolio that will drive the next phase of growth, with insight from Smith+Nephew customers and Key Opinion Leaders. This event will be held at the New York Stock Exchange from 2pm to 6pm GMT / 9am to 1pm EST on 11 December.

​Both events will be led by Chief Executive Officer Deepak Nath, accompanied by Chief Financial Officer John Rogers and members of the Executive Committee. Further information will be provided in due course, and participants are encouraged to attend both events, either in person or virtually.

​In person attendance at these events requires pre-registration. Investors and analysts should register via Smith+Nephew’s website at https://www.smith-nephew.com/en/about-us/investors.

​The sessions will also be webcast and the presentations made available via the website.

Share on:

Latest Company News

Smith & Nephew to host Capital Markets Days in London and New York

Smith & Nephew will hold Capital Markets Days on 8 December in London and 11 December in New York to outline its new strategy, mid-term priorities, and portfolio growth plans.

Smith & Nephew Plc delivers strong H1 with profit up 31%

Smith+Nephew reported 5.0% underlying revenue growth and a 30.6% rise in operating profit for H1 2025. EPS rose 36.6% to 33.5¢ and free cash flow surged to $244m. The company also announced a $500m share buyback for H2, supported by strong cash generation and margin expansion.

Smith & Nephew appoints David King as Non-Executive Director

Smith & Nephew Plc announces the addition of David King as an independent Non-Executive Director, effective July 1, 2025, enhancing their healthcare leadership.

Smith & Nephew Plc 12-Point Plan increasingly delivering better financial performance

Smith & Nephew reports strong financial results for 2024 with significant revenue and profit growth, driven by innovation and strategic restructuring.

Smith & Nephew Plc delivers Q3 revenue of $1,412 million, 4% growth

Smith & Nephew's Q3 2024 update shows a 4% revenue growth to $1,412M. Despite China headwinds, US Orthopaedics and Sports Medicine excelled.

Smith & Nephew Plc transforming into a higher growth and more profitable business

Smith & Nephew plc (LON:SN, NYSE:SNN) reports a robust financial performance for Q2 and H1 2024, showing significant revenue and profit growth.

    Search

    Search